You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 285 No. 5, February 7, 2001 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Research Opportunities for Specific Diseases and Disorders
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (31)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Topic Collections
 •Statistics and Research Methods
 •Drug Therapy
 •Drug Therapy, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Development of Antimicrobial Agents in the Era of New and Reemerging Infectious Diseases and Increasing Antibiotic Resistance

Gail H. Cassell, PhD; John Mekalanos, PhD

JAMA. 2001;285:601-605.

During the past 2 decades, new infectious diseases have appeared and old ones previously thought to be controlled have reemerged. New and reemerging infectious agents will continue to pose serious threats well into the 21st century. The prediction that the threat of infectious disease may not diminish is supported by evidence that infectious agents cause many chronic diseases and cancer of previous unknown etiology. Moreover, the utility of existing antimicrobial agents is rapidly eroding, tipping the balance in favor of multidrug-resistant pathogens, and there appear to be few, if any, new classes of drugs currently in clinical development. The need for research directed toward development of new antibiotics has never been greater. Advances in research technologies and microbial genome sequencing in the past decade have led to identification of a large number of new targets. Functional genomics and integrative biology should validate these targets and provide the best opportunity for developing effective new therapies, improved diagnostic techniques, and better tools to understand host-pathogen interactions.


Author Affiliations: Infectious Disease Research and Clinical Investigation, Eli Lilly & Co, Indianapolis, Ind (Dr Cassell); Departments of Microbiology and Pediatrics, University of Alabama at Birmingham (Dr Cassell); and Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, Mass (Dr Mekalanos).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Eradication of Bacteria in Suspension and Biofilms Using Methylene Blue-Loaded Dynamic Nanoplatforms
Wu et al.
Antimicrob. Agents Chemother. 2009;53:3042-3048.
ABSTRACT | FULL TEXT  

Selective Inhibitors of Bacterial DNA Adenine Methyltransferases
Mashhoon et al.
J Biomol Screen 2006;11:497-510.
ABSTRACT  

Photodynamic Inactivation of Bacillus Spores, Mediated by Phenothiazinium Dyes
Demidova and Hamblin
Appl. Environ. Microbiol. 2005;71:6918-6925.
ABSTRACT | FULL TEXT  

Antibiotic Resistance: What Is the Impact of Agricultural Uses of Antibiotics on Children's Health?
Shea
Pediatrics 2003;112:253-258.
ABSTRACT | FULL TEXT  

Daptomycin Pharmacokinetics and Safety following Administration of Escalating Doses Once Daily to Healthy Subjects
Dvorchik et al.
Antimicrob. Agents Chemother. 2003;47:1318-1323.
ABSTRACT | FULL TEXT  

The role of genomics in antimicrobial discovery
Mills
J Antimicrob Chemother 2003;51:749-752.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2001 American Medical Association. All Rights Reserved.